所有图片(1)
About This Item
经验公式（希尔记法）:
C18H21NO4 · HCl
CAS号:
分子量:
351.82
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
oxycodone
制造商/商品名称
EDQM
药品控制
USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O
InChI
1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1
InChI key
MUZQPDBAOYKNLO-RKXJKUSZSA-N
基因信息
human ... OPRM1(4988)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Oxycodone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
μ 和 κ 阿片受体激动剂。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - STOT SE 3
靶器官
Central nervous system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Caitlin M Vander Weele et al.
The European journal of neuroscience, 40(7), 3041-3054 (2014-09-12)
While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psychostimulant administration have been well studied; however, such changes have
Salvatore V Colucci et al.
Clinical drug investigation, 34(6), 421-429 (2014-04-24)
Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage
Carrie L Wade et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 421-428 (2014-07-26)
The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing ∼$53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Tomohisa Mori et al.
Journal of pharmacological sciences, 126(1), 47-55 (2014-08-22)
The rewarding effects of μ-receptor agonists can be suppressed under several pain conditions. We recently showed that clinically used μ-receptor agonists possess efficacies for relieving the neuropathic pain induced by chemotherapeutic drug in rats; however, it is possible that the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门